NASDAQ: CNSPCns Pharmaceuticals Inc Stock
$0.20-0.01 (-4.76%)
Updated Apr 25, 2024
CNSP Price
$0.20
Fair Value Price
$0.07
Market Cap
$2.17M
52 Week Low
$0.19
52 Week High
$2.98
P/E
-0.04x
P/B
-0.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.38
Operating Cash Flow
-$14M
Beta
0.73
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CNSP Overview
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CNSP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNSP ($0.20) is overvalued by 210% relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CNSP ($0.20) is not significantly undervalued (210%) relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CNSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNSP due diligence checks available for Premium users.
Be the first to know about important CNSP news, forecast changes, insider trades & much more!
CNSP News
Valuation
CNSP fair value
Fair Value of CNSP stock based on Discounted Cash Flow (DCF)
Price
$0.20
Fair Value
$0.07
Overvalued by
203.92%
CNSP ($0.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNSP ($0.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNSP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
15.41x
Market
40.97x
CNSP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.49x
Industry
5.8x
CNSP's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
CNSP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.7M
Liabilities
$6.1M
Debt to equity
-1.38
CNSP's short-term liabilities ($6.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNSP's short-term assets ($1.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNSP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CNSP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
-$2.2k
Financing
$2.2M
CNSP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNSP vs Biotech Stocks
Cns Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.